Switch theme
Sign up to access all valuation multiples
Genscript Biotech Corp is a China-based provider of life science research services and products. it is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, The company estimates that over two-thirds of GenScript valuation is from its ownership stake in Legend.
2002
6.9K+
LTM Revenue $8.5B
LTM EBITDA -$599M
$2.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genscript Biotech has a last 12-month revenue of $8.5B and a last 12-month EBITDA of -$599M.
In the most recent fiscal year, Genscript Biotech achieved revenue of $108M and an EBITDA of -$32.1M.
Genscript Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genscript Biotech valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $80.4M | $108M | $1.1B | $8.5B | XXX |
| Gross Profit | $39.0M | $39.1M | $52.7M | XXX | XXX |
| Gross Margin | 49% | 36% | 5% | XXX | XXX |
| EBITDA | -$45.5M | -$32.1M | -$124M | -$599M | XXX |
| EBITDA Margin | -57% | -30% | -11% | -7% | XXX |
| Net Profit | -$44.7M | -$29.2M | -$12.3M | XXX | XXX |
| Net Margin | -56% | -27% | -1% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Genscript Biotech's stock price is HKD 13 (or $2).
Genscript Biotech has current market cap of HKD 28.4B (or $3.6B), and EV of HKD 17.3B (or $2.2B).
See Genscript Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $3.6B | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Genscript Biotech has market cap of $3.6B and EV of $2.2B.
Genscript Biotech's trades at 2.0x LTM EV/Revenue multiple, and -28.8x LTM EBITDA.
Analysts estimate Genscript Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Genscript Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.2B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | -18.0x | XXX | XXX | XXX |
| P/E | 37.2x | XXX | XXX | XXX |
| P/E/Growth | 0.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGenscript Biotech's NTM/LTM revenue growth is -100%
Genscript Biotech's revenue per employee for the last fiscal year averaged $16K, while opex per employee averaged $15K for the same period.
Over next 12 months, Genscript Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Genscript Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Genscript Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 914% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -11% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 286% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $16K | XXX | XXX | XXX | XXX |
| Opex per Employee | $15K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 25% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 52% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 96% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genscript Biotech acquired XXX companies to date.
Last acquisition by Genscript Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Genscript Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Genscript Biotech founded? | Genscript Biotech was founded in 2002. |
| Where is Genscript Biotech headquartered? | Genscript Biotech is headquartered in Hong Kong. |
| How many employees does Genscript Biotech have? | As of today, Genscript Biotech has 6.9K+ employees. |
| Is Genscript Biotech publicy listed? | Yes, Genscript Biotech is a public company listed on HKG. |
| What is the stock symbol of Genscript Biotech? | Genscript Biotech trades under 01548 ticker. |
| When did Genscript Biotech go public? | Genscript Biotech went public in 2015. |
| Who are competitors of Genscript Biotech? | Similar companies to Genscript Biotech include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Genscript Biotech? | Genscript Biotech's current market cap is $3.6B |
| What is the current revenue of Genscript Biotech? | Genscript Biotech's last 12-month revenue is $8.5B. |
| What is the current EBITDA of Genscript Biotech? | Genscript Biotech's last 12-month EBITDA is -$599M. |
| What is the current EV/Revenue multiple of Genscript Biotech? | Current revenue multiple of Genscript Biotech is 2.0x. |
| What is the current EV/EBITDA multiple of Genscript Biotech? | Current EBITDA multiple of Genscript Biotech is -28.8x. |
| What is the current revenue growth of Genscript Biotech? | Genscript Biotech revenue growth between 2023 and 2024 was 914%. |
| Is Genscript Biotech profitable? | Yes, Genscript Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
